Epilepsy (Central Nervous System) Drugs In Development, 2021 Clinical Landscape Report - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Epilepsy (Central Nervous System) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Epilepsy (Central Nervous System) - Drugs In Development, 2021, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Epilepsy (Central Nervous System) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Epilepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epilepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 12, 32, 29, 4, 124, 38 and 5 respectively. Similarly, the Universities portfolio in Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 25 and 3 molecules, respectively.

Epilepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Epilepsy (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Epilepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Epilepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Epilepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Epilepsy (Central Nervous System)

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/bzvqxk

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900